2021 Update
Clinical Research Currents has temporarily suspended publication.
Learn about our new clinical trials startup, Sparrow Search, connecting patients with clinical trials.
PharmaVoice 100 by Marie Jung The July/August Special Issue of PharmaVoice Magazine features 100 individuals designated by the publication as some of the “Most Inspiring” people in the life sciences, and the event celebrating the honorees took place in New York City in September. Influenced by the inclusion of adjectives Read more
by Marie Jung The announcement of the merging of two non-profit research organizations called Calibr and TSRI sparked excitement in the field of medical research on October 20th, 2016. Dr. Peter Shultz*, the leader of both institutions, shared this insight on the new formation: “The affiliation between TSRI and Calibr Read more
by Marie Jung BioCom’s October 13th Breakfast Meeting on “Zika Virus and Emerging Diseases” was not one to be missed, but in case you had something else going on, Clinical Currents is here to update you. The talk was sponsored by DLA Piper, and was led by Karen Midthun, M.D., Read more
FDA Begins Consultation on Two ICH Guidelines Posted 08 September 2016By Michael Mezher The US Food and Drug Administration (FDA) has issued two new International Council for Harmonisation (ICH) guidelines for public consultation: one on multi-regional clinical trials (MRCTs) and one on microsampling in study animals. Once ICH adopts Read more
This is the first of an ongoing series offering predictions of future changes to the clinical research landscape by John Neal, *CPA, BS, CRCP, founder and CEO of PCRS Network, LLC, and member of the ACRP Board of Trustees… “The first prediction: While major changes will occur, changes will not happen quickly. However, when they do occur, they will be disruptive and many people working in the industry will be displaced…” Follow the ACRP blog for more predictions.
http://www.nbcsandiego.com/on-air/as-seen-on/Bridget6pm0829_San-Diego-391680861.html
Ronald A. DePinho, M.D., President, University of Texas MD Anderson Cancer Center, talks about the types of medicines and treatments that are in clinical trials and how they could be the game-changer needed in the fight against cancer. (Published Monday, Aug. 29, 2016)
Scripps Health has entered into a decades-long partnership with one of the nation’s leading cancer research centers that will lead to greater access to treatments and clinical trials…What may be most important to those battling cancer will be the access to clinical trials managed by MD Anderson.,,“We’re very interested in expanding access to clinical trials in communities like San Diego,” Ronald A. DePinho, M.D., President, University of Texas MD Anderson Cancer Center said.
Another San Diego scientist has made it onto a genius list…Liangfang Zhang, Ph.D. Professor, Department of Nanoengineering. Moores Cancer Center , was selected for the Popular Science nationwide search of the 10 most innovative young minds in science and engineering. Nanoparticles can shuttle medicines to diseased tissues with incredible precision, Read more
BIO, a lobbying group for the biotechnology industry, said the success rate of a drug in Phase-I development was 10% for all indications outside of oncology, according to its new report. Cancer drugs have only a 5% success rate.
Bridging the ‘cultural gap in drug development’ with Silicon-Valley technology
Sensors, computer vision, machine learning, and cloud computing are enabling preclinical researchers to conduct higher quality studies in a shorter period of time. (Outsourcing-Pharma.com)